Jonathan Golledge1, Carla Ewels2, Reinhold Muller2, Phillip J Walker3. 1. Queensland Research Centre for Peripheral Vascular Disease, School of Medicine and Dentistry, James Cook University, Townsville, Australia; Department of Vascular and Endovascular Surgery, The Townsville Hospital, Townsville, Australia. Electronic address: jonathan.golledge@jcu.edu.au. 2. Queensland Research Centre for Peripheral Vascular Disease, School of Medicine and Dentistry, James Cook University, Townsville, Australia; School of Public Health, Tropical Medicine and Rehabilitation Sciences, James Cook University, Townsville, Australia. 3. University of Queensland School of Medicine, Discipline of Surgery and Centre for Clinical Research, Brisbane, Australia; Department of Vascular Surgery, The Royal Brisbane and Women's Hospital, Brisbane, Australia.
Abstract
OBJECTIVE: The aim of this study was to compare the ability of eGFR calculated by modification of diet in renal disease (MDRD), Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) and Lund-Malmö formulae in predicting major adverse events in peripheral vascular disease (PVD) patients. METHODS: We prospectively recruited 2137 patients, measured serum creatinine to calculate eGFR using three different formulae and grouped patients into eGFR categories ≥90, 60-89, 45-59, 30-44, 15-29 and <15 ml/min/1.73 m(2). Patients were followed up for a median of 1.3 (inter-quartile range 0.3-3.6) years. The primary outcome was the combined incidence of myocardial infarction, stroke or death. The ability of eGFR categories defined with the different formulae to predict outcome was assessed using the net reclassification index. RESULTS: 1450 (67.9%), 1515 (70.9%) and 1813 (84.8%) patients had eGFR <90 ml/min/1.73 m(2) according to the CKD-EPI, MDRD and Lund-Malmö formulae, respectively. Using the CKD-EPI formula 276 (12.9%) patients were reclassified to a different eGFR category in comparison to the MDRD formula and the prediction of outcome was improved (net reclassification index 0.106, p < 0.001). Using the Lund-Malmö formula 563 (26.3%) patients were reclassified to a different eGFR category in comparison to the MDRD formula and the prediction of outcome was improved (net reclassification index 0.108, p < 0.001). Classification using the CKD-EPI and Lund-Malmö formulae was equally effective at predicting outcome (net reclassification index - 0.002, p = 0.397). CONCLUSIONS: eGFR categories determined with the CKD-EPI and Lund-Malmö formulae are equally effective at predicting major adverse events in patients with PVD.
OBJECTIVE: The aim of this study was to compare the ability of eGFR calculated by modification of diet in renal disease (MDRD), Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) and Lund-Malmö formulae in predicting major adverse events in peripheral vascular disease (PVD) patients. METHODS: We prospectively recruited 2137 patients, measured serum creatinine to calculate eGFR using three different formulae and grouped patients into eGFR categories ≥90, 60-89, 45-59, 30-44, 15-29 and <15 ml/min/1.73 m(2). Patients were followed up for a median of 1.3 (inter-quartile range 0.3-3.6) years. The primary outcome was the combined incidence of myocardial infarction, stroke or death. The ability of eGFR categories defined with the different formulae to predict outcome was assessed using the net reclassification index. RESULTS: 1450 (67.9%), 1515 (70.9%) and 1813 (84.8%) patients had eGFR <90 ml/min/1.73 m(2) according to the CKD-EPI, MDRD and Lund-Malmö formulae, respectively. Using the CKD-EPI formula 276 (12.9%) patients were reclassified to a different eGFR category in comparison to the MDRD formula and the prediction of outcome was improved (net reclassification index 0.106, p < 0.001). Using the Lund-Malmö formula 563 (26.3%) patients were reclassified to a different eGFR category in comparison to the MDRD formula and the prediction of outcome was improved (net reclassification index 0.108, p < 0.001). Classification using the CKD-EPI and Lund-Malmö formulae was equally effective at predicting outcome (net reclassification index - 0.002, p = 0.397). CONCLUSIONS:eGFR categories determined with the CKD-EPI and Lund-Malmö formulae are equally effective at predicting major adverse events in patients with PVD.
Authors: Malindu E Fernando; Robert G Crowther; Peter A Lazzarini; Kunwarjit S Sangla; Scott Wearing; Petra Buttner; Jonathan Golledge Journal: J Diabetes Sci Technol Date: 2019-06-16
Authors: Nicola W Burton; Zanfina Ademi; Stuart Best; Maria A Fiatarone Singh; Jason S Jenkins; Kenny D Lawson; Anthony S Leicht; Yorgi Mavros; Yian Noble; Paul Norman; Richard Norman; Belinda J Parmenter; Jenna Pinchbeck; Christopher M Reid; Sophie E Rowbotham; Lisan Yip; Jonathan Golledge Journal: BMC Public Health Date: 2016-11-09 Impact factor: 3.295
Authors: Sophie E Rowbotham; Jenna L Pinchbeck; Georgina Anderson; Bernie Bourke; Michael Bourke; T Christian Gasser; Rene Jaeggi; Jason S Jenkins; Corey S Moran; Susan K Morton; Christopher M Reid; Ramesh Velu; Lisan Yip; Joseph V Moxon; Jonathan Golledge Journal: Trials Date: 2017-11-16 Impact factor: 2.279
Authors: Diana Thomas Manapurathe; Joseph Vaughan Moxon; Smriti Murali Krishna; Sophie Rowbotham; Frank Quigley; Jason Jenkins; Michael Bourke; Bernard Bourke; Rhondda E Jones; Jonathan Golledge Journal: J Am Heart Assoc Date: 2019-03-19 Impact factor: 5.501
Authors: Malindu Eranga Fernando; Robert George Crowther; Margaret Cunningham; Peter Anthony Lazzarini; Kunwarjit Singh Sangla; Jonathan Golledge Journal: BMC Endocr Disord Date: 2015-10-23 Impact factor: 2.763
Authors: Tejas P Singh; Joseph V Moxon; Genevieve N Healy; Yvonne Cadet-James; Jonathan Golledge Journal: BMC Cardiovasc Disord Date: 2018-05-16 Impact factor: 2.298
Authors: Jonathan Golledge; Sophie Rowbotham; Ramesh Velu; Frank Quigley; Jason Jenkins; Michael Bourke; Bernie Bourke; Shivshankar Thanigaimani; Dick C Chan; Gerald F Watts Journal: J Am Heart Assoc Date: 2020-03-14 Impact factor: 5.501
Authors: Jenna L Pinchbeck; Joseph V Moxon; Sophie E Rowbotham; Michael Bourke; Sharon Lazzaroni; Susan K Morton; Evan O Matthews; Kerolos Hendy; Rhondda E Jones; Bernie Bourke; Rene Jaeggi; Danella Favot; Frank Quigley; Jason S Jenkins; Christopher M Reid; Ramesh Velu; Jonathan Golledge Journal: J Am Heart Assoc Date: 2018-10-02 Impact factor: 5.501
Authors: Dylan R Morris; Tristan A Skalina; Tejas P Singh; Joseph V Moxon; Jonathan Golledge Journal: J Am Heart Assoc Date: 2018-10-16 Impact factor: 5.501